Abstract
Haemophilia B, a deficiency in clotting factor IX (FIX), occurs in about 1 in 25.000 males. Of these patients, approximately 40% are characterized as having severe haemophilia (FIX below 1% of normal). Although the use of plasma-derived or rFIX has extended the lifespan of these patients, they remain afflicted by a variety of sequelae of the disease. Interestingly, a relatively small increase in the levels of FIX results in a dramatic increase in the quality of life, requiring rFIX substitution only prior to dental and surgical procedures. This latter trait of the disease suggests that gene therapy only needs to achieve modest expression and makes this disease a prime candidate for proof-of-concept of gene therapy. Current protocols for gene therapy entail the risk of malignant transformation. In addition the viral vectors may cause substantial pathology. Hence, the field requires the development of inherently safe gene therapy. Recently, developed protocols have been developed to transduce peripheral blood cells with high efficiency using RNA as a vector. These protocols in which the inherently safe RNA-based gene therapy approach will be validated and implemented for haemophilia B will provide in turn providing important proof-of concept for this type of therapy for more prevalent diseases but requires optimization of this strategy, probably by enhancing RNA stability using artificial nucleotides and modified UTRs, enhanced production of protein by codon usage optimization and the use of multi-cistronic constructs, and enhanced secretion of the protein employing target cell-tailored secretion signals.
Keywords: clotting factor IX, DNA Transfection, GFP expression, RNA stability, X-linked recessive disorder
Current Genomics
Title: RNA-Based Gene Therapy for Haemophilia B
Volume: 6 Issue: 6
Author(s): M. P. Peppelenbosch, F. Milano, C. V. Ferreira, A. Knapinska, S. H. Diks and C. A. Spek
Affiliation:
Keywords: clotting factor IX, DNA Transfection, GFP expression, RNA stability, X-linked recessive disorder
Abstract: Haemophilia B, a deficiency in clotting factor IX (FIX), occurs in about 1 in 25.000 males. Of these patients, approximately 40% are characterized as having severe haemophilia (FIX below 1% of normal). Although the use of plasma-derived or rFIX has extended the lifespan of these patients, they remain afflicted by a variety of sequelae of the disease. Interestingly, a relatively small increase in the levels of FIX results in a dramatic increase in the quality of life, requiring rFIX substitution only prior to dental and surgical procedures. This latter trait of the disease suggests that gene therapy only needs to achieve modest expression and makes this disease a prime candidate for proof-of-concept of gene therapy. Current protocols for gene therapy entail the risk of malignant transformation. In addition the viral vectors may cause substantial pathology. Hence, the field requires the development of inherently safe gene therapy. Recently, developed protocols have been developed to transduce peripheral blood cells with high efficiency using RNA as a vector. These protocols in which the inherently safe RNA-based gene therapy approach will be validated and implemented for haemophilia B will provide in turn providing important proof-of concept for this type of therapy for more prevalent diseases but requires optimization of this strategy, probably by enhancing RNA stability using artificial nucleotides and modified UTRs, enhanced production of protein by codon usage optimization and the use of multi-cistronic constructs, and enhanced secretion of the protein employing target cell-tailored secretion signals.
Export Options
About this article
Cite this article as:
Peppelenbosch P. M., Milano F., Ferreira V. C., Knapinska A., Diks H. S. and Spek A. C., RNA-Based Gene Therapy for Haemophilia B, Current Genomics 2005; 6 (6) . https://dx.doi.org/10.2174/138920205774483052
DOI https://dx.doi.org/10.2174/138920205774483052 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomedical Imaging in Implantable Drug Delivery Systems
Current Drug Targets Editorial [ Hot Topic:Complex Carbohydrates (Guest Editors: Nasir-ud-Din & Daniel C. Hoessli) ]
Current Organic Chemistry Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology Diabetic Retinopathy: Current and New Treatment Options
Current Diabetes Reviews New Uses of Melatonin as a Drug; A Review
Current Medicinal Chemistry A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry Interventional Radiology in Paediatrics
Current Pediatric Reviews Nanoemulsion: A Novel Eon in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Charge Deficient Analogues of the Natural Polyamines
Current Pharmaceutical Design Use of Grape Polyphenols for Promoting Human Health: A Review of Patents
Recent Patents on Food, Nutrition & Agriculture Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
Current Pharmaceutical Design Designed Multiple Ligands for Cancer Therapy
Current Medicinal Chemistry Analysis the Effectiveness of Oral Massage Using Sono-elastography
Neuroscience and Biomedical Engineering (Discontinued) Aspartic Proteases of Human Pathogenic Fungi are Prospective Targets for the Generation of Novel and Effective Antifungal Inhibitors
Current Enzyme Inhibition “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Role of Sulfonamide Group in Matrix Metalloproteinase Inhibitors
Current Medicinal Chemistry